We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Vaccine Designed to Shield AIDS Carriers

By Labmedica staff writers
Posted on 09 Feb 2007
A two-stage vaccine against HIV that is designed to benefit individuals already carrying the virus has demonstrated nearly complete protection against developing clinical AIDS in early stage trials with non-human primates.

The vaccine, which was developed by Geovax Incorporated (Atlanta, GA, USA), comprises a combination of DNA and modified vaccinia Ankara (MVA) to stimulate production of anti-HIV antibodies and anti-HIV T cells. More...
MVA virus, which has been engineered to express foreign genes, is widely considered as the vaccinia virus strain of choice for clinical investigation because of its high safety profile.

In preclinical trials the DNA/MVA vaccine was 96% effective in protecting non-human primates against developing clinical AIDS. Twenty-two out of 23 non-human primates that received the vaccine were protected against developing clinical signs of AIDS. The animal that was not protected received only a partial dose of vaccine. Over 83% of the unvaccinated controls (5/6) died of clinical AIDS within eight months after receiving live HIV, and all the animals had levels of virus in the blood stream 10 to 100-fold higher than in typical HIV-1 infected humans.



Related Links:
Geovax Incorporated

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Size assessment of patient-derived material from various tauopathies (Aragonès Pedrola J. et al., PNAS (2025); DOI: 10.1073/pnas.2502847122)

First Direct Measurement of Dementia-Linked Proteins to Enable Early Alzheimer’s Detection

The disease process in Alzheimer’s begins long before memory loss or cognitive decline becomes apparent. During this silent phase, misfolded proteins gradually form amyloid fibrils, which accumulate in... Read more

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.